Medios AG, together with its subsidiaries, engages in the wholesale of specialty pharmaceutical drugs in Germany. It operates through Pharmaceutical Supply and Patient-Specific Therapies segments. The Pharmaceutical Supply segment offers products on oncology, neurology, autoimmunology, ophthalmology, infectiology, and hemophilia diseases. The Patient-Specific Therapies segment manufactures medications for patients on behalf of pharmacies; and patient-specific therapies for dispensing individually dosed tablets. The company was founded in 2016 and is based in Berlin, Germany.
Earnings for Medios AG (ILM1.DE)
Earnings in 2023 (TTM): $31.78 M
According to Medios AG's latest financial reports the company's current earnings (TTM) are $31.78 M. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Medios AG
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $31.78 M | $20.35 M |
| 2022 | $30.1 M | $19.83 M |
| 2021 | $14.69 M | $8.01 M |
| 2020 | $9.63 M | $5.98 M |
| 2019 | $15.39 M | $10.56 M |
| 2018 | $7.98 M | $4.68 M |
| 2017 | $7.26 M | $4.47 M |
| 2016 | $-2,284,643 | $-3,431,211 |
| 2015 | $-174,054 | $-174,054 |
| 2014 | $-35,851 | $-35,885 |
| 2013 | $-178,702 | $-178,702 |
| 2012 | $-220,496 | $-220,495 |
| 2011 | $ | $ |
| 2010 | $ | $ |